Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma

Glen J. Weiss,Lisa Blaydorn,Julia Beck,Kirsten Bornemann-Kolatzki,Howard Urnovitz, Ekkhard Schütz,Vivek Khemka

Investigational New Drugs（2019）

引用 7|浏览0

暂无评分

摘要

The authors would like to note an error in Figures 1 and 2 of this paper. The graph in Figure 1 incorrectly reflected the overall survival (OS), when it should have displayed the progression-free survival (PFS). The caption and median PFS values were correct.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要